ACURA PHARMACEUTICALS, INC. (NASDAQ:ACUR) Files An 8-K Shareholder Director NominationsItem 5.08 Shareholder Director Nominations
Acura Pharmaceuticals, Inc. (the “Company”) plans to hold its 2017 Annual Meeting of Stockholders on November 8, 2017. Since this date is more than 30 days after the anniversary of the Company’s 2016 Annual Meeting of Stockholders, the Company is providing the due date for submission of any qualified stockholder proposal or qualified stockholder nominations. The deadlines for stockholder proposals listed in the Company's 2016 Proxy Statement on Schedule 14A, as filed with the SEC on March 7, 2017 are no longer applicable. In accordance with Rule 14a-5(f) and Rule 14a-8(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), we are requiring that written notice from a stockholder interested in bringing business before the Company’s 2017 Annual Meeting of Stockholders including , to the extent provided for under New York law, any notice for nominating a director candidate for election at the Company’s 2017 Annual Meeting of Stockholders on Schedule14N, must be received by the Company no later than 5:00 p.m., Central time, on August 31, 2017 at the Company’s principal executive office, 616 N. North Court, Palatine Illinois 60067, addressed to the attention of the Secretary.
About ACURA PHARMACEUTICALS, INC. (NASDAQ:ACUR)
Acura Pharmaceuticals, Inc. is a pharmaceutical company. The Company is engaged in the research, development and commercialization of technologies and products intended to address medication abuse and misuse. The Company has discovered and developed three platform technologies, which can be used to develop multiple products. The Company’s Oxaydo Tablets (oxycodone HCl, CII), which utilizes the Aversion Technology, is an approved and immediate-release (IR) oxycodone product in the United States. The Company’s Impede technology products include Nexafed and Nexafed Sinus Pressure + Pain. Its third deterrent technology is Limitx, which is designed to retard the release of active drug ingredients when too many tablets are accidently or purposefully ingested. The Company’s Aversion and Limitx technologies are intended to address methods associated with opioid and its Impede technology is directed at the extraction and conversion of pseudoephedrine into methamphetamine.